Browse Studies — Arctuva

Phase 1

Phase I/II Trial of Neoadjuvant Combination of Ficerafusp Alfa, Pembrolizumab, and SBRT for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

The study is an open-label phase I/II clinical trial. The study will enroll patients to receive neoadjuvant SBRT plus 1 or 2 doses of neoadjuvant pembrolizumab…

Head and Neck Squamous Cell CarcinomaHPV-Negative Squamous Cell Carcinoma

Estimated

~$10 – $6,250

Washington University School of MedicineNCT07552558

Phase 1

Phase I Decitabine Dose-Tolerance in Surgically Resectable HPV-Negative Head and Neck Cancer

This phase I trial tests the safety, side effects, and best dose of decitabine in combination with standard of care surgery, radiation, and/or chemotherapy and…

Human Papillomavirus-Negative Neck Squamous Cell CarcinomaResectable Head and Neck Squamous Cell CarcinomaResectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell Carcinoma+2 more

Estimated

~$10 – $6,250

Mayo ClinicNCT06997094

Phase 1

Pilot Study of Induction Therapy Followed by Response-adaptive Treatment and Dynamic Changes in Circulating Tumor DNA in Locoregionally Advanced HPV Negative Head and Neck Squamous Cell Carcinoma

This clinical trial will assess whether or not blood based biomarker testing can be used to personalize cancer treatment for patients with locally advanced hea…

HPV-Negative Squamous Cell Carcinoma

Estimated

~$10 – $6,250

University of ChicagoNCT06005324